These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37004464)

  • 1. Economic evaluation of 18F-FDG PET/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation - A cost-effectiveness analysis.
    Schnitzer ML; Buchner J; Biechele G; Grawe F; Ingenerf M; von Münchhausen N; Kaiser CG; Kunz WG; Froelich MF; Schmid-Tannwald C; Rübenthaler J
    Eur J Radiol; 2023 Jun; 163():110803. PubMed ID: 37004464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of MRI, CE-CT and 18F-FDG PET/CT for detecting colorectal liver metastases eligible for hepatic resection.
    Schnitzer ML; von Münchhausen N; Biechele G; Runtemund J; Grawe F; Geyer T; Kaiser CG; Haag F; Rübenthaler J; Froelich MF
    Front Oncol; 2023; 13():1161738. PubMed ID: 37554160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation.
    Sivesgaard K; Larsen LP; Sørensen M; Kramer S; Schlander S; Amanavicius N; Bharadwaz A; Tønner Nielsen D; Viborg Mortensen F; Morre Pedersen E
    Eur Radiol; 2018 Nov; 28(11):4735-4747. PubMed ID: 29736846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis.
    Burian E; Palla B; Callahan N; Pyka T; Wolff C; von Schacky CE; Schmid A; Froelich MF; Rübenthaler J; Makowski MR; Gassert FG
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3870-3877. PubMed ID: 35606526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-Up 18F-FDG PET/CT versus Contrast-Enhanced CT after Ablation of Liver Metastases of Colorectal Carcinoma-A Cost-Effectiveness Analysis.
    Schnitzer ML; Froelich MF; Gassert FG; Huber T; Gresser E; Schwarze V; Nörenberg D; Todica A; Rübenthaler J
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic performance of
    Samim M; Molenaar IQ; Seesing MFJ; van Rossum PSN; van den Bosch MAAJ; Ruers TJM; Borel Rinkes IHM; van Hillegersberg R; Lam MGEH; Verkooijen HM
    Surg Oncol; 2017 Mar; 26(1):37-45. PubMed ID: 28317583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results.
    Kuehl H; Antoch G; Stergar H; Veit-Haibach P; Rosenbaum-Krumme S; Vogt F; Frilling A; Barkhausen J; Bockisch A
    Eur J Radiol; 2008 Aug; 67(2):362-371. PubMed ID: 18155866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEUS compared with CECT, MRI, and FDG-PET/CT for diagnosing CRC liver metastases: a diagnostic test accuracy systematic review and meta-analysis.
    Lund M; Bjerre TA; Grønbæk H; Mortensen FV; Andersen PK
    Expert Rev Gastroenterol Hepatol; 2024 Sep; 18(9):541-549. PubMed ID: 39315472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
    Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
    Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Gassert FG; Rübenthaler J; Cyran CC; Rink JS; Schwarze V; Luitjens J; Gassert FT; Makowski MR; Schoenberg SO; Mayerhoefer ME; Tamandl D; Froelich MF
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3268-3276. PubMed ID: 33686457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases.
    Nielsen K; Scheffer HJ; Pieters IC; van Tilborg AA; van Waesberghe JH; Oprea-Lager DE; Meijerink MR; Kazemier G; Hoekstra OS; Schreurs HW; Sietses C; Meijer S; Comans EF; van den Tol PM
    BMC Med Imaging; 2014 Aug; 14():27. PubMed ID: 25103913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Added Diagnostic Value of Transcatheter CT Hepatic Arteriography for Intraprocedural Detection of Previously Unknown Colorectal Liver Metastases During Percutaneous Ablation and Impact on the Definitive Treatment Plan.
    van der Lei S; Opperman J; Dijkstra M; Kors N; Boon R; van den Bemd BAT; Timmer FEF; Nota IMGC; van den Bergh JE; de Vries JJJ; Scheffer HJ; Geboers B; Neuss T; Schouten E; Lissenberg-Witte BI; Puijk RS; Meijerink MR
    Cardiovasc Intervent Radiol; 2023 Sep; 46(9):1257-1266. PubMed ID: 37491521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early PET/CT after radiofrequency ablation in colorectal cancer liver metastases: is it useful?
    Liu ZY; Chang ZH; Lu ZM; Guo QY
    Chin Med J (Engl); 2010 Jul; 123(13):1690-4. PubMed ID: 20819630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer.
    Lejeune C; Bismuth MJ; Conroy T; Zanni C; Bey P; Bedenne L; Faivre J; Arveux P; Guillemin F
    J Nucl Med; 2005 Dec; 46(12):2020-8. PubMed ID: 16330566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effective imaging for resectability of liver lesions in colorectal cancer: an economic decision model.
    Saing S; Haywood P; Duncan JK; Ma N; Cameron AL; Goodall S
    ANZ J Surg; 2018 Jun; 88(6):E507-E511. PubMed ID: 28982209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI.
    Cantwell CP; Setty BN; Holalkere N; Sahani DV; Fischman AJ; Blake MA
    J Comput Assist Tomogr; 2008; 32(5):738-44. PubMed ID: 18830103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT: a meta-analysis.
    Tsili AC; Alexiou G; Naka C; Argyropoulou MI
    Acta Radiol; 2021 Mar; 62(3):302-312. PubMed ID: 32506935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis.
    Westwood M; Joore M; Grutters J; Redekop K; Armstrong N; Lee K; Gloy V; Raatz H; Misso K; Severens J; Kleijnen J
    Health Technol Assess; 2013 Apr; 17(16):1-243. PubMed ID: 23611316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
    Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
    Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.